November 2021, Galderma bought California-based Alastin, a firm specialising in specialist skincare products, for an undisclosed price. In June 2022, Galderma announced positive results in two Phase III trials for liquid botulinum toxin A, showing RelabotulinumtoxinA significantly reduced frown line severity and was well tolerated. This result primes the company to apply for approval in the US and other global markets. Also in June 2022, Galderma announced positive data from Phase III trial, showing efficacy and safety of nemolizumab in patients with prurigo nodularis. Nemolizumab is a monoclonal antibody that blocks the signaling of IL-31, a neuroimmune cytokine involved in the pathogenesis of prurigo nodularis. Activities Galderma is specialized in the research, development and commercialization of skin care products and treatments across aesthetics, consumer care and prescription medicine. Galderma provides a range of over-the-counter and prescription dermatological products for skin care, aesthetics and treatment of conditions including acne, rosacea, psoriasis and other steroid-responsive dermatoses (SRD), onychomycosis (fungal nail infections), pigmentary disorders, skin cancer and skin aging. Galderma's activities are divided into three business units: aesthetics, consumer care and prescription medicine. Galderma's products are sold in more than 100 countries. Aesthetics In 2007, Galderma and Ipsen signed a licensing agreement for the distribution of the botulinum toxin Dysport, known as Azzalure in the European Union, for the improvement of glabellar lines (frown lines between the eyes). More than 40 million treatments have been performed in the United States and the European Union. The main brands are Restylane, Azzalure, Dysport, Alluzience and Sculptra. Consumer care Galderma's products are available over-the-counter to consumers. The main consumer care brands are Cetaphil, with its range of skin care products for all ages; Benzac and Differin OTC for mild-to-moderate acne; and Loceryl, used to treat fungal nail infections, and Alastin. Prescription Medicine Disease areas are atopic dermatitis, dermato-oncology and psoriasis. The main brands are Aklief, Benzac, Cetaphil, Epiduo, Epiduo Forte, Loceryl, Differin, Soolantra, Mirvaso, Oracea and Metvix. Research and development The company invests substantially in research and development and sources new treatments from its own activities and from its partnerships with others. It divides its research and development departments between six sites: Lausanne, Switzerland Zug, Switzerland Uppsala, Sweden Dallas, Texas Bridgewater, New Jersey Baie d’Urfé, Canada Production Galderma has manufacturing facilities at the following locations: The Alby-sur-Chéran plant in France, inaugurated in 1994, supplies over 70 countries. The Baie d'Urfé (Montreal) facility in Canada started production